Article
Predictive and Prognostic Potential of TP53 in Patients With Advanced Non-Small-Cell Lung Cancer Treated With EGFR-TKI: Analysis of a Phase III Randomized Clinical Trial (CTONG 0901).
Clinical lung cancer - 1 Mar 2021
Li Xiang-Meng, Li Wen-Feng, Lin Jun-Tao, Yan Hong-Hong, Tu Hai-Yan, Chen Hua-Jun, Wang Bin-Chao, Wang Zhen, Zhou Qing, Zhang Xu-Chao, Su Jian, Chen Rui-Lian, Wu Yi-Long, Yang Jin-Ji
Abstract excerpt
BACKGROUND: Mutations in TP53 are commonly found in patients with epidermal growth factor receptor (EGFR) mutant advanced non-small-cell lung cancer (NSCLC). In this study, we determined the predictive and prognostic potential of different subtypes of TP53 using data from a phase III randomized trial (CTONG 0901). PATIENTS AND METHODS: The trial enrolled 195 patients who had undergone next-generation sequencing...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.